Given the complex nature of weight regulating pathways and biotechnological innovations, our focus has shifted to include investigations involving the role of the gut microbiome (GMB) in AIWG. Pre-clinical data suggest that antipsychotic drugs reduce or disturb microbial diversity causing a shift towards pro-obesogenic bacterial species associated with metabolic dysregulation and obesity. Furthermore, the GMB has also been shown to influence brain development and the predisposition towards various psychiatric conditions.
One of our upcoming studies aims to investigate the role of the GMB in the risk for schizophrenia and AP-induced metabolic abnormalities. Investigators will perform cross-sectional analyses of the GMB composition in (A) healthy volunteers matched with (B) non-antipsychotic treated schizophrenia patients and (C) schizophrenia patients chronically exposed to antipsychotic drugs. Patients of group (B) will be assessed prospectively (baseline, week 3 and week 6) for metabolic indices (e.g. weight gain, fasting glucose). Recruitment for this study is anticipated to begin in January 2016. Please contact us if you would like to be involved as a research subject.